About the Program:
Target Audience:
This activity is intended for physicians, physician assistants, advanced practice nurses, general practitioners and other health care professionals involved in the treatment and management of patients who have or are at risk of HCV infection.
Learning Objectives:
Upon completion of the program, participants should be able to:
- Describe the changing demographics of and risk factors for CHC
- Improve the rate of testing and diagnosis of patients with CHC
- Link patients with diagnosed CHC to timely and appropriate HCV therapy
- Provide optimal, individualized HCV therapy to patients with CHC that results in improved outcomes
Release Date: May 29, 2020
Expiration Date: May 29, 2021
Estimated time to complete each Module: 30-60 minutes
Media: Web
Faculty:
Paul Kwo, MD
Director of Hepatology
Professor of Medicine
Stanford University School of Medicine
Palo Alto, California
Mark Sulkowski, MD
Professor of Medicine and Medical Director
Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Stacey Trooskin, MD, PhD
Physician and Director of Viral Hepatitis Program
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania
Back to Top
Joint Accreditation Statement:
|
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Back to Top
Credit Designation:
Module 1: COVID-19 and HCV Discussion
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2: Epidemiology, Demographics and Current HCV Guidelines
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3: Testing and Diagnosis of Patients with CHC
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4: Linkage to HCV Care and Pre-Treatment Management
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 5: Optimizing HCV Treatment - Simplified Therapy and PWID Management
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Back to Top
Disclosure of Conflicts of Interest:
Postgraduate Institute for Medicine (PIM) requires instructors,
planners, managers and other individuals who are in a position to
control the content of this activity to disclose any real or apparent
conflict of interest (COI) they may have as related to the content of
this activity. All identified COI are thoroughly vetted and resolved
according to PIM policy. PIM is committed to providing its learners with
high quality CME activities and related materials that promote
improvements or quality in healthcare and not a specific proprietary
business interest of a commercial interest.
The faculty reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
Paul Kwo, MD:
- Consulting Fees: Abbvie, Gilead, Ribavirin Pregnancy Registry
- Contracted Research: Abbvie, BMS, Gilead, HCV Target Registries
|
Mark Sulkowski, MD:
- Consulting Fees: AbbVie, Gilead
- Contracted Research: Gilead, AbbVie, Proteus Digital Health
|
Stacey Trooskin, MD:
|
The planners and managers reported the following financial relationships
or relationships to products or devices they or their spouse/life
partner have with commercial interests related to the content of this
CME activity:
The PIM and ViralEd planners and managers have nothing to disclose.
Back to Top
Instructions for Participation and Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period, May 29, 2020 through May 29, 2021, participants must read the learning objectives and faculty disclosures and study the educational activity.
If
you wish to receive acknowledgment for completing this activity, please
complete the evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 15185. Upon registering and successfully completing the activity evaluation, your certificate
will be made available immediately.
Back to Top
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or
investigational uses of agents that are not indicated by the FDA. The
planners of this activity do not recommend the use of any agent outside
of the labeled indications.
The opinions expressed in the educational activity are those of the
faculty and do not necessarily represent the views of the planners.
Please refer to the official prescribing information for each product
for discussion of approved indications, contraindications, and warnings.
Back to Top
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant to
serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient's conditions and possible contraindications
on dangers in use, review of any applicable manufacturer's product
information, and comparison with recommendations of other authorities.
Back to Top
Computer System Requirements
This program requires HTML 5 enabled web browsers such as: Microsoft Edge, Mozilla Firefox, Apple Safari or Google Chrome.
Back to Top
For CME Accreditation Questions, please click HERE
This activity is supported by an independent educational grant from Gilead Sciences Medical Affairs
Jointly provided by the Postgraduate Institute for Medicine and ViralEd, Inc.
|